- Home
- ALLR vs QNRX Comparison
ALLR vs QNRX Comparison
Compare ALLR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- QNRX
- Stock Information
- Founded
- ALLR 2004
- QNRX 2018
- Country
- ALLR United States
- QNRX United States
- Employees
- ALLR N/A
- QNRX N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- ALLR Health Care
- QNRX Health Care
- Exchange
- ALLR Nasdaq
- QNRX Nasdaq
- Market Cap
- ALLR 4.0M
- QNRX 3.3M
- IPO Year
- ALLR N/A
- QNRX N/A
- Fundamental
- Price
- ALLR $0.87
- QNRX $8.53
- Analyst Decision
- ALLR
- QNRX
- Analyst Count
- ALLR 0
- QNRX 0
- Target Price
- ALLR N/A
- QNRX N/A
- AVG Volume (30 Days)
- ALLR 660.5K
- QNRX 527.1K
- Earning Date
- ALLR 05-09-2025
- QNRX 05-13-2025
- Dividend Yield
- ALLR N/A
- QNRX N/A
- EPS Growth
- ALLR N/A
- QNRX N/A
- EPS
- ALLR N/A
- QNRX N/A
- Revenue
- ALLR N/A
- QNRX N/A
- Revenue This Year
- ALLR N/A
- QNRX N/A
- Revenue Next Year
- ALLR N/A
- QNRX N/A
- P/E Ratio
- ALLR N/A
- QNRX N/A
- Revenue Growth
- ALLR N/A
- QNRX N/A
- 52 Week Low
- ALLR $0.61
- QNRX $5.01
- 52 Week High
- ALLR $20.44
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- ALLR 36.97
- QNRX 56.56
- Support Level
- ALLR $1.02
- QNRX $6.21
- Resistance Level
- ALLR $1.06
- QNRX $9.90
- Average True Range (ATR)
- ALLR 0.08
- QNRX 0.90
- MACD
- ALLR -0.03
- QNRX 0.21
- Stochastic Oscillator
- ALLR 12.56
- QNRX 64.14
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.